SCHEMBL25974272

SCHEMBL25974272

CC1C(NC(=O)c2cc3nc(-c4ccccc4)cc(-c4ccccc4)n3n2)CN1C(=O)OC(C)(C)C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.58
HTT P42858 4/20 0.58
ALDH1A1 P00352 10/20 0.50
HPGD P15428 8/20 0.50
MAPT P10636 6/20 0.50
LMNA P02545 5/20 0.50
TP53 P04637 4/20 0.50
NPSR1 Q6W5P4 4/20 0.50
MAPK1 P28482 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
GAA P10253 2/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HSD17B10 Q99714 3/20 0.44
ADRA2A P08913 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25969448 0.85 KDM4E (0.69) KDM4EHTTALDH1A1HPGDMAPT
SCHEMBL25974158 0.85 KDM4E (0.66) KDM4EHTTALDH1A1HPGDMAPT
SCHEMBL25974180 0.78 KDM4E (0.54) KDM4EHTTALDH1A1HPGDMAPT
SCHEMBL25974275 0.78 KDM4E (0.66) KDM4EHTTALDH1A1HPGDMAPT
SCHEMBL25974262 0.76 KDM4E (0.56) KDM4EHTTALDH1A1HPGDMAPT
SCHEMBL25969141 0.76 KDM4E (0.77) KDM4EHTTALDH1A1HPGDMAPT
SCHEMBL25974199 0.75 KDM4E (0.60) KDM4EHTTALDH1A1HPGDMAPT
SCHEMBL25430390 0.74 KDM4E (0.96) KDM4EHTTALDH1A1HPGDMAPT
SCHEMBL1718809 0.74 KDM4E (1.00) KDM4EHTTALDH1A1HPGDMAPT
SCHEMBL25974169 0.73 OPRK1 (0.61) KDM4EHTTALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250161307-A1 PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE JANSSEN PHARMACEUTICA NV (BE) 2025-05-22 US disclosed
EP-4469454-A1 PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE Janssen Pharmaceutica NV (BE) 2024-12-04 EP disclosed
WO-2023141866-A1 PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 WO disclosed
WO-2023141866-A1 PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250161307-A1 PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE SMOX, SRM, SMS KDM4E 1480/4885HTT 3140/4885ALDH1A1 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.